Case 3: Front Line Therapy Options in ET


Experts in essential thrombocythemia review first line treatment options.

Ruben Mesa, MD: Prithviraj, the guidelines offer 3 options as frontline therapy. As I like to say, there’s both the art and the science of medicine. The guidelines help provide the science. The art is which of the medicines you choose. How do you choose between those frontline options in ET?

Prithviraj Bose, MD: Hydroxyurea, pegylated interferon, and maybe even anagrelide could be considered frontline options. However, I do not use anagrelide as a frontline option. I keep it to hydroxyurea and interferon. My view thus far with interferon has been that I tend to offer it if the patient is very young, younger than 40, or if pregnancy is a consideration. Otherwise, I tend to default to Hydrea. As this panel is well aware, the leukemogenicity has never been proven. It sometimes comes up and tends to be an area of some controversy, but since it has never been proven and it is an effective, inexpensive, convenient, and safe drug, I usually go with hydroxyurea.

This transcript has been edited for clarity.

Related Videos
Video 11 - "Treating Patients With RCC Who Progress Following Adjuvant Therapy"
Video 10 - "RCC: Informing Treatment Decisions with Clinical Trial Data"
Video 9 - "KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma"
Video 8 - "Clinical Pearls for Optimal Management of mHSPC"
Video 7 - "Multidisciplinary Approach in mHSPC Management "
Video 6 - "Treatment Considerations in High Disease Burden and Comorbidities"
Video 5 - "Pivotal Trials in mHSPC"
Video 4 - "ARASENS Trial- Darolutamide in mHSPC"
Video 3 - "Treatment Intensification in Metastatic Prostate Cancer"
Video 2 - "Treatment Options for mHSPC"